As of Feb 27
| +0.41 / +37.61%|
The 2 analysts offering 12-month price forecasts for Cyclacel Pharmaceuticals Inc have a median target of 9.50, with a high estimate of 10.00 and a low estimate of 9.00. The median estimate represents a +533.33% increase from the last price of 1.50.
The current consensus among 1 polled investment analysts is to Hold stock in Cyclacel Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.